

# COMPANY FACT SHEET



INOVIQ Ltd (ASX:IIQ) is developing and commercialising next-generation exosome capture tools and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases


## Investment highlights

- Proprietary technology platforms for biomarker isolation and detection
- Products in-market for exosome research & bladder cancer
- Multi-product pipeline for detection and monitoring of breast, ovarian and other cancers targeting large global markets
- Compelling early data in breast and ovarian cancers
- Multiple key inflection points over next 12 months
- Experienced management with track record in healthcare leadership, diagnostic development and commercialisation
- Strong cash position of \$15.4m to fund operations and pipeline development

## Market need and commercial opportunity

- Initial focus on unmet needs for non-invasive, accurate and reliable diagnostic tests for earlier detection of cancer
- Cancers are often diagnosed at late-stage after symptoms have appeared, resulting in poor prognosis
- Earlier detection improve treatment options, patient outcomes and survival<sup>1</sup>

### 5-year survival rates by stage at diagnosis<sup>1</sup>



## Global cancer diagnostics market

Global cancer diagnostics market valued at **US\$250b<sup>2</sup>**. INOVIQ is targeting markets worth over **US\$15b** for some of the world's most common and deadliest cancers.

\$4.2b

BREAST  
CANCER

\$1.9b

OVARIAN  
CANCER

\$3.3b

PROSTATE  
CANCER

\$2.4b

PANCREATIC  
CANCER

### Market data (\*14/10/22)

ASX code:	IIQ
Share price:	\$0.61*
Market cap:	\$56m*
Shares on issue:	92,018,702*
Cash at bank:	\$15.4m (30/6/22)

### Board and management

Dr Geoff Cumming	Non-Executive Chairman
Mr Max Johnston	Non-Executive Director
Mr Philip Powell	Non-Executive Director
Prof Allan Cripps AO	Non-Executive Director
Dr Leeanne Hinch	Chief Executive Officer
Dr Greg Rice	Chief Scientific Officer
Mr Mark Edwards	CFO & Company Secretary
Dr Rocco Iannello	BD / Licensing Director

### Contacts

Dr Leeanne Hinch | CEO  
[lhinch@inoviq.com](mailto:lhinch@inoviq.com)  
+61 400 414 416

Dr Rocco Iannello | BD/L Director  
[riannello@inoviq.com](mailto:riannello@inoviq.com)  
+61 408 547 394

Jane Lowe | Investor Relations  
[Jane.lowe@irdepartment.com.au](mailto:Jane.lowe@irdepartment.com.au)  
+61 411 117 774

<sup>1</sup> SEER 18 2010-2016; <sup>2</sup> Grand View Research 2019. <https://www.grandviewresearch.com/press-release/global-cancer-diagnostics-market>

## Collaborations and partnerships for IIQ's diagnostic pipeline

- Research & Option Agreement with the University of Queensland (AU) to develop an exosome-based ovarian cancer screening test
- Master Services Agreement with specialty contract diagnostics organisation ResearchDx (USA) to develop and validate SubB2M-based immunoassays for breast and ovarian cancer monitoring
- Contract Research Agreement with Nicoya Lifesciences Inc (CA) to transfer, develop and evaluate a SubB2M-based SPR test for cancer risk assessment on the next-gen Alto digital SPR instrument

## Our products and pipeline

PRODUCT	INDICATION	PLATFORM	USE	RESEARCH	ASSAY DEVELOPMENT	CLINICAL DEVELOPMENT	REGISTRATION
hTERT <sup>1</sup>	Bladder Cancer	ICC	Adjunct to cytology	[Progress bar from Research to Clinical Development]			★ In-market
EXO-NET-RUO	Exosome Capture	Device	Research tool	[Progress bar from Research to Clinical Development]			★ In-market
Exosome-OC <sup>2</sup> (OCRF-7)	Ovarian Cancer	Multiomic	Screening	[Progress bar from Research to Assay Development]			
SubB2M-BCM	Breast Cancer	Immunoassay	Monitoring	[Progress bar from Research to Assay Development]			2023
SubB2M-OCM	Ovarian Cancer	Immunoassay	Monitoring	[Progress bar from Research to Assay Development]			2023
SubB2M-SPR	Multi-cancer	SPR	Risk assessment	[Progress bar from Research to Assay Development]			
SubB2M-PCS	Prostate Cancer	Immunoassay	Detection	[Progress bar from Research to Assay Development]			
SubB2M-PaC	Pancreatic Cancer	Immunoassay	Detection	[Progress bar from Research to Assay Development]			
BARD1-Ovarian <sup>3</sup>	Ovarian Cancer	Immunoassay	Detection	[Progress bar from Research to Assay Development]			
BARD1-Breast <sup>3</sup>	Breast Cancer	Immunoassay	Detection	[Progress bar from Research to Assay Development]			

RUO = Research Use Only; ICC = Immunocytochemistry; 1. Adjunct to urine cytology to assist the detection of bladder cancer; 2. Progression subject to completion of review; 3 Umbrella Research & Option Agreement with UQ

## Our patented technologies and products

### SubB2M

Highly specific probe that detects the pan-cancer marker Neu5Gc found in multiple human cancers.

Applications for **multi-cancer detection and monitoring**, including improving performance of existing cancer biomarker tests.

Feasibility data showing a SubB2M-based SPR test detects breast and ovarian cancers across all stages with over 95% sensitivity and 100% specificity.

### NETs

NETs platform enables the capture of target analytes from any biofluid.

Initial applications enabling **exosome isolation, biomarker discovery and diagnostics**.

EXO-NET<sup>®</sup> research tools available in-market to capture exosomes with speed, purity and yield advantages.



### BARD1

Biomarker technology covering various BARD1 tumour markers and methods of use for diagnostic applications.

Applications for **earlier cancer detection**.

Feasibility data showing high accuracy of BARD1 autoantibody tests to detect ovarian and breast cancers.

### HTERT

Anti-hTERT antibody technology that detects hTERT that is upregulated in various human cancers.<sup>1</sup>

Applications in **immunocytochemistry (ICC)**.

hTERT ICC test available in-market as an adjunct to urine cytology to assist the diagnosis of bladder cancer.

